Advanced Gastroesophageal Cancer

Publication Date: January 5, 2023

Key Points

Key Points

  • Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
  • Most gastric and gastrointestinal junction tumors are adenocarcinoma.
  • Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.

Treatment

...Treatment...

...notherapy and Targeted Therapy for Advanced Ga...


...First-line Therapy...

...endation 1.1For HER2-negative patien...

...mmendation 1.2For HER2-negative patients with...

...n 1.3For patients with ESCC and PD...

...commendation 1.4For patients with ESCC, and PD-L...

....5For patients with HER2-positive gastric or...


...Second- or Third-line Th...

Recommendation 2.1For patients with adva...

...ion 2.2For HER2-positive patients...